BRIEF-Janux Therapeutics, Bristol Myers Squibb Sign Exclusive Global License To Develop Tumor-Activated Solid Tumor Therapy

Reuters01-22

BRIEF-Janux <a href="https://laohu8.com/S/LENZ">Therapeutics</a>, Bristol Myers Squibb Sign Exclusive Global License To Develop Tumor-Activated Solid Tumor Therapy

Jan 22 (Reuters) - Janux Therapeutics Inc JANX.O:

JANUX THERAPEUTICS ANNOUNCES COLLABORATION AND EXCLUSIVE WORLDWIDE LICENSE AGREEMENT WITH BRISTOL MYERS SQUIBB TO DEVELOP A NOVEL TUMOR-ACTIVATED THERAPEUTIC FOR SOLID TUMORS
JANUX THERAPEUTICS INC - TO RECEIVE UP TO $50 MILLION UPFRONT, $800 MILLION IN MILESTONES
JANUX THERAPEUTICS: UNDER TERMS, CO IS ELIGIBLE TO RECEIVE DEVELOPMENT, REGULATORY & COMMERCIAL MILESTONES UP TO ABOUT $800 MILLION IN AGGREGATE
JANUX THERAPEUTICS INC - AS PART OF COLLABORATION, CO WILL COMPLETE PRECLINICAL DEVELOPMENT UP TO IND SUBMISSION
JANUX THERAPEUTICS INC - AS PART OF COLLABORATION, BRISTOL WILL HOLD IND & BE RESPONSIBLE FOR SUBSEQUENT DEVELOPMENT & GLOBAL COMMERCIALIZATION
JANUX THERAPEUTICS INC - CO ALSO ENTITLED TO TIERED ROYALTIES ON GLOBAL SALES

Source text: ID:nBw1sx9M9a

Further company coverage: JANX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605495985?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-22 20:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605495985","market":"us","top_or_hot":-1,"title":"BRIEF-Janux Therapeutics, Bristol Myers Squibb Sign Exclusive Global License To Develop Tumor-Activated Solid Tumor Therapy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Janux <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Bristol Myers Squibb Sign Exclusive Global License To Develop Tumor-Activated Solid Tumor Therapy</title></head><body><p><span>Jan 22 (Reuters)</span><span> - </span>Janux Therapeutics Inc <span>JANX.O</span>:</p><ul><li><p>JANUX THERAPEUTICS ANNOUNCES COLLABORATION AND EXCLUSIVE WORLDWIDE LICENSE AGREEMENT WITH BRISTOL MYERS SQUIBB TO DEVELOP A NOVEL TUMOR-ACTIVATED THERAPEUTIC FOR SOLID TUMORS</p></li><li><p>JANUX THERAPEUTICS INC - TO RECEIVE UP TO $50 MILLION UPFRONT, $800 MILLION IN MILESTONES</p></li><li><p>JANUX THERAPEUTICS:  UNDER TERMS, CO IS ELIGIBLE TO RECEIVE DEVELOPMENT, REGULATORY &amp; COMMERCIAL MILESTONES UP TO ABOUT $800 MILLION IN AGGREGATE</p></li><li><p>JANUX THERAPEUTICS INC - AS PART OF COLLABORATION, CO WILL COMPLETE PRECLINICAL DEVELOPMENT UP TO IND SUBMISSION</p></li><li><p>JANUX THERAPEUTICS INC - AS PART OF COLLABORATION, BRISTOL  WILL HOLD IND &amp; BE RESPONSIBLE FOR SUBSEQUENT DEVELOPMENT &amp; GLOBAL COMMERCIALIZATION</p></li><li><p>JANUX THERAPEUTICS INC - CO ALSO ENTITLED TO TIERED ROYALTIES ON GLOBAL SALES</p></li></ul><p>Source text: <span>ID:nBw1sx9M9a</span></p><p>Further company coverage: <span>JANX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Janux Therapeutics, Bristol Myers Squibb Sign Exclusive Global License To Develop Tumor-Activated Solid Tumor Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Janux Therapeutics, Bristol Myers Squibb Sign Exclusive Global License To Develop Tumor-Activated Solid Tumor Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-22 20:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Janux <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Bristol Myers Squibb Sign Exclusive Global License To Develop Tumor-Activated Solid Tumor Therapy</title></head><body><p><span>Jan 22 (Reuters)</span><span> - </span>Janux Therapeutics Inc <span>JANX.O</span>:</p><ul><li><p>JANUX THERAPEUTICS ANNOUNCES COLLABORATION AND EXCLUSIVE WORLDWIDE LICENSE AGREEMENT WITH BRISTOL MYERS SQUIBB TO DEVELOP A NOVEL TUMOR-ACTIVATED THERAPEUTIC FOR SOLID TUMORS</p></li><li><p>JANUX THERAPEUTICS INC - TO RECEIVE UP TO $50 MILLION UPFRONT, $800 MILLION IN MILESTONES</p></li><li><p>JANUX THERAPEUTICS:  UNDER TERMS, CO IS ELIGIBLE TO RECEIVE DEVELOPMENT, REGULATORY &amp; COMMERCIAL MILESTONES UP TO ABOUT $800 MILLION IN AGGREGATE</p></li><li><p>JANUX THERAPEUTICS INC - AS PART OF COLLABORATION, CO WILL COMPLETE PRECLINICAL DEVELOPMENT UP TO IND SUBMISSION</p></li><li><p>JANUX THERAPEUTICS INC - AS PART OF COLLABORATION, BRISTOL  WILL HOLD IND &amp; BE RESPONSIBLE FOR SUBSEQUENT DEVELOPMENT &amp; GLOBAL COMMERCIALIZATION</p></li><li><p>JANUX THERAPEUTICS INC - CO ALSO ENTITLED TO TIERED ROYALTIES ON GLOBAL SALES</p></li></ul><p>Source text: <span>ID:nBw1sx9M9a</span></p><p>Further company coverage: <span>JANX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nTUA7LK4Q0:1","article_id":"2605495985","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605495985","pubTimestamp":1769083893,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Janux Therapeutics, Bristol Myers Squibb Sign Exclusive Global License To Develop Tumor-Activated Solid Tumor TherapyJan 22 (Reuters) - Janux Therapeutics Inc JANX.O:JANUX THERAPEUTICS ANNOUNCES","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","JANX":"Janux Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"BRIEF-Janux Therapeutics与百时美施贵宝签署开发肿瘤激活实体瘤疗法的全球独家许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JANX":0.9},"content_text":"BRIEF-Janux Therapeutics, Bristol Myers Squibb Sign Exclusive Global License To Develop Tumor-Activated Solid Tumor TherapyJan 22 (Reuters) - Janux Therapeutics Inc JANX.O:JANUX THERAPEUTICS ANNOUNCES COLLABORATION AND EXCLUSIVE WORLDWIDE LICENSE AGREEMENT WITH BRISTOL MYERS SQUIBB TO DEVELOP A NOVEL TUMOR-ACTIVATED THERAPEUTIC FOR SOLID TUMORSJANUX THERAPEUTICS INC - TO RECEIVE UP TO $50 MILLION UPFRONT, $800 MILLION IN MILESTONESJANUX THERAPEUTICS:  UNDER TERMS, CO IS ELIGIBLE TO RECEIVE DEVELOPMENT, REGULATORY & COMMERCIAL MILESTONES UP TO ABOUT $800 MILLION IN AGGREGATEJANUX THERAPEUTICS INC - AS PART OF COLLABORATION, CO WILL COMPLETE PRECLINICAL DEVELOPMENT UP TO IND SUBMISSIONJANUX THERAPEUTICS INC - AS PART OF COLLABORATION, BRISTOL  WILL HOLD IND & BE RESPONSIBLE FOR SUBSEQUENT DEVELOPMENT & GLOBAL COMMERCIALIZATIONJANUX THERAPEUTICS INC - CO ALSO ENTITLED TO TIERED ROYALTIES ON GLOBAL SALESSource text: ID:nBw1sx9M9aFurther company coverage: JANX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605495985","isCrawlerRequest":true}